Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience
about
Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer.A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).Treatment of head and neck cancer in the elderly.Overall Survival of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Nimotuzumab in the Real World.MRI features can predict EGFR expression in lower grade gliomas: A voxel-based radiomic analysis.
P2860
Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment outcome of nimotuzum ...... a single institute experience
@en
Treatment outcome of nimotuzum ...... a single institute experience.
@nl
type
label
Treatment outcome of nimotuzum ...... a single institute experience
@en
Treatment outcome of nimotuzum ...... a single institute experience.
@nl
prefLabel
Treatment outcome of nimotuzum ...... a single institute experience
@en
Treatment outcome of nimotuzum ...... a single institute experience.
@nl
P2093
P2860
P356
P1433
P1476
Treatment outcome of nimotuzum ...... a single institute experience
@en
P2093
Mayra Ramos-Suzarte
Shuping Xu
Xianhong Bai
P2860
P304
33391-33407
P356
10.18632/ONCOTARGET.8516
P407
P577
2016-03-31T00:00:00Z